Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein

Journal of Infectious Diseases

Volumn 212, Issue 6, 2015, Pages 978-989

  Olsen, Anja W ^a   Follmann, Frank ^a   Erneholm, Karin ^a,b   Rosenkrands, Ida ^a   Andersen, Peter ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

broadly neutralizing Ab; Chlamydia trachomatis; vaccine; VD4

Indexed keywords

BACTERIAL VACCINE; CHLAMYDIA TRACHOMATIS VACCINE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; EPITOPE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; LIPOSOME; MAJOR OUTER MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY; OUTER MEMBRANE PROTEIN; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; BACTERIAL COUNT; CD4+ T LYMPHOCYTE; CHLAMYDIASIS; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FEMALE GENITAL SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; T CELL DEPLETION; VD4 REGION; ANIMAL; CD8+ T LYMPHOCYTE; CHEMISTRY; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; MICE;

EID: 84940766628     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv137     Document Type: Conference Paper

References (50)

1. WHO. Global incidence and prevalence of selected curable sexually transmitted infections-2008. Geneva, Switzerland: World Health Organization, 2012.
2. Moore T, Ekworomadu CO, Eko FO, et al. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis 2003; 188:617-24.
3. Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005; 5:149-61.
4. Li W, Murthy AK, Guentzel MN, et al. Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge. Infect Immun 2010; 78:3942-9.
5. Farris CM, Morrison RP. Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model. Infect Immun 2011; 79:986-96.
6. Hansen J, Jensen KT, Follmann F, Agger EM, Theisen M, Andersen P. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J Infect Dis 2008; 198:758-67.
7. Rockey DD, Wang J, Lei L, Zhong G. Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev Vaccines 2009; 8:1365-77.
8. Olsen AW, Andersen P, Follmann F. Characterization of protective immune responses promoted by human antigen targets in a urogenital Chlamydia trachomatis mouse model. Vaccine 2014; 32:685-92.
9. Kubo A, Stephens RS. Characterization and functional analysis of PorB, a Chlamydia porin and neutralizing target. Mol Microbiol 2000; 38:772-80.
10. Crane DD, Carlson JH, Fischer ER, et al. Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. Proc Natl Acad Sci U S A 2006; 103:1894-9.
11. Pal S, Theodor I, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun 2001; 69:6240-7.
12. Toye B, Zhong GM, Peeling R, Brunham RC. Immunologic characterization of a cloned fragment containing the species-specific epitope from the major outer membrane protein of Chlamydia trachomatis. Infect Immun 1990; 58:3909-13.
13. Su H, Caldwell HD. Immunogenicity of a synthetic oligopeptide corresponding to antigenically common T-helper and B-cell neutralizing epitopes of the major outer membrane protein of Chlamydia trachomatis. Vaccine 1993; 11:1159-66.
14. Villeneuve A, Brossay L, Paradis G, Hebert J. Determination of neutralizing epitopes in variable domains I and IV of the major outermembrane protein from Chlamydia trachomatis serovar K. Microbiology 1994; 140 (Pt 9):2481-7.
15. Murdin AD, Su H, Klein MH, Caldwell HD. Poliovirus hybrids expressing neutralization epitopes from variable domains I and IV of the major outer membrane protein of Chlamydia trachomatis elicit broadly crossreactive C. trachomatis-neutralizing antibodies. Infect Immun 1995; 63:1116-21.
16. Motin VL, de la Maza LM, Peterson EM. Immunization with a peptide corresponding to chlamydial heat shock protein 60 increases the humoral immune response in C3H mice to a peptide representing variable domain 4 of the major outer membrane protein of Chlamydia trachomatis. Clin Diagn Lab Immunol 1999; 6:356-63.
17. Su H, Parnell M, Caldwell HD. Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection. Vaccine 1995; 13:1023-32.
18. Baehr W, Zhang YX, Joseph T, et al. Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes. Proc Natl Acad Sci USA 1988; 85:4000-4.
19. Stephens RS, Wagar EA, Schoolnik GK. High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis. J Exp Med 1988; 167:817-31.
20. Peterson EM, Cheng X, Markoff BA, Fielder TJ, de la Maza LM. Functional and structural mapping of Chlamydia trachomatis speciesspecific major outer membrane protein epitopes by use of neutralizing monoclonal antibodies. Infect Immun 1991; 59:4147-53.
21. Qu Z, Cheng X, de la Maza LM, Peterson EM. Analysis of the humoral response elicited in mice by a chimeric peptide representing variable segments I and IV of the major outer membrane protein of Chlamydia trachomatis. Vaccine 1994; 12:557-64.
22. Olsen AW, Follmann F, Jensen K, et al. Identification of CT521 as a frequent target of Th1 cells in patients with urogenital Chlamydia trachomatis infection. J Infect Dis 2006; 194:1258-66.
23. Olsen AW, Follmann F, Højrup P, et al. Identification of human T-cell targets recognized during the Chlamydia trachomatis genital infection. J Infect Dis 2007; 196:1546-52.
24. Brandt L, Oettinger T, Holm A, Andersen AB, Andersen P. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol 1996; 157: 3527-33.
25. Lindenstrom T, Agger EM, Korsholm KS, et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009; 182: 8047-55.
26. Byrne GI, Stephens RS, Ada G, et al. Workshop on in vitro neutralization of Chlamydia trachomatis: summary of proceedings. J Infect Dis 1993; 168:415-20.
27. Ortiz L, Angevine M, Kim SK, Watkins D, DeMars R. T-cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovar-specific immune responses in infected humans. Infect Immun 2000; 68:1719-23.
28. Kim SK, DeMars R. Epitope clusters in the major outer membrane protein of Chlamydia trachomatis. Curr Opin Immunol 2001; 13: 429-36.
29. Agger EM, Rosenkrands I, Hansen J, et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 2008; 3:e3116.
30. Peterson EM, Cheng X, Qu Z, de la Maza LM. The effect of orientation within a chimeric peptide on the immunogenicity of Chlamydia trachomatis epitopes. Mol Immunol 1996; 33:335-9.
31. Morrison RP, Feilzer K, Tumas DB. Gene knockout mice establish a primary protective role for major histocompatibility complex class IIrestricted responses in Chlamydia trachomatis genital tract infection. Infect Immun 1995; 63:4661-8.
32. + T cells. Infect Immun 2000; 68:6979-87.
33. + T cells. Infect Immun 2001; 69:2643-9.
34. Morrison SG, Morrison RP. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J Immunol 2005; 175:7536-42.
35. + T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection. Infect Immun 2010; 78:4374-83.
36. Cotter TW, Meng Q, Shen ZL, Zhang YX, Su H, Caldwell HD. Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infect Immun 1995; 63:4704-14.
37. Sturdevant GL, Caldwell HD. Innate immunity is sufficient for the clearance of Chlamydia trachomatis from the female mouse genital tract. Pathog Dis 2014; 72:70-3.
38. Maxion HK, Liu W, Chang MH, Kelly KA. The infecting dose of Chlamydia muridarum modulates the innate immune response and ascending infection. Infect Immun 2004; 72:6330-40.
39. Werninghaus K, Babiak A, Gross O, et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med 2009; 206:89-97.
40. Lindenstrom T, Woodworth J, Dietrich J, Aagaard C, Andersen P, Agger EM. Vaccine-induced Th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset. Infect Immun 2012; 80:3533-44.
41. + T cells. Infect Immun 2010; 78:2272-82.
42. Jaffar Z, Ferrini ME, Girtsman TA, Roberts K. Antigen-specific Treg regulate Th17-mediated lung neutrophilic inflammation, B-cell recruitment and polymeric IgA and IgM levels in the airways. Eur J Immunol 2009; 39:3307-14.
43. Su H, Morrison RP, Watkins NG, Caldwell HD. Identification and characterization of T helper cell epitopes of the major outer membrane protein of Chlamydia trachomatis. J Exp Med 1990; 172:203-12.
44. Ortiz L, Demick KP, Petersen JW, et al. Chlamydia trachomatis major outer membrane protein (MOMP) epitopes that activate HLA class IIrestricted T cells from infected humans. J Immunol 1996; 157:4554-67.
45. Arno JN, Xie C, Jones RB, Van Der Pol B. Identification of T cells that respond to serovar-specific regions of the Chlamydia trachomatis major outer membrane protein in persons with serovar E infection. J Infect Dis 1998; 178:1713-8.
46. Suchland RJ, Eckert LO, Hawes SE, Stamm WE. Longitudinal assessment of infecting serovars of Chlamydia trachomatis in Seattle public health clinics: 1988-1996. Sex Transm Dis 2003; 30:357-61.
47. Lysen M, Osterlund A, Rubin CJ, Persson T, Persson I, Herrmann B. Characterization of ompA genotypes by sequence analysis of DNA from all detected cases of Chlamydia trachomatis infections during 1 year of contact tracing in a Swedish County. J Clin Microbiol 2004; 42:1641-7.
48. Spaargaren J, Verhaest I, Mooij S, et al. Analysis of Chlamydia trachomatis serovar distribution changes in the Netherlands (1986-2002). Sex Transm Infect 2004; 80:151-2.
49. Mossman D, Beagley KW, Landay AL, et al. Genotyping of urogenital Chlamydia trachomatis in Regional New South Wales, Australia. Sex Transm Dis 2008; 35:614-6.
50. Machado AC, Bandea CI, Alves MF, et al. Distribution of Chlamydia trachomatis genovars among youths and adults in Brazil. J Med Microbiol 2011; 60:472-6.